I'm a corporate partner based in London where I use my experience to advise clients - ranging from start-ups to multinationals, investment banks and private equity funds - on mergers and acquisitions (and divestitures), IPO's and other securities offerings, private equity and venture capital investments/exits, joint ventures, strategic collaborations and corporate reorganisations.

My primary focus is on advising clients operating in the life sciences, healthcare and technology, media and telecoms sectors. You'll find me ranked in the Legal 500 UK, 2020 legal directory in the fields of M&A, Venture Capital and Pharmaceuticals and Biotechnology.

The life sciences and healthcare industries are changing rapidly. In life sciences, exciting science is resulting in new drugs and medical devices being developed that will in time drastically improve health outcomes. Meanwhile, companies with promising drugs in development continue to get acquired by larger pharmaceutical companies so that they can replenish their drug pipelines. In healthcare new and innovative ways of delivering better health outcomes more efficiently are being developed, challenging healthcare providers to keep up with the rapid rates of technological change. At all times, we use our knowledge of the life sciences, healthcare and technology sectors to provide our clients with focused and commercial advice.

Over the years I've found that most of the transactions on which I advise have a cross-border dimension. I therefore have significant experience of dealing with the challenges presented by complex international projects, including solving complex legal issues and bridging cultural differences. Bird & Bird also has an excellent international network and I regularly work with colleagues in other offices to help clients implement their transactions successfully.

I am admitted as a Solicitor of the Senior Courts of England and Wales and the Eastern Caribbean Supreme Court in the British Virgin Islands and I hold an LL.B. in Law with Economics from Durham University. I also serve on the Finance and Tax Advisory Committee of the BioIndustry Association.

  • Advised Chiesi Farmaceutici S.p.A. on the in-licence of Raxone® -- an orphan drug used in the treatment of Leber's hereditary optic neuropathy, a rare hereditary eye disease that leads to severe vision loss -- from Santhera Pharmaceuticals Holding AG for approximately €93 million.
  • Advised National Digital Infrastructure Fund and RPMI Railpen on the £50 million funding round in Community Fibre, the ultra-fast full-fibre internet service provider.
Education
  • Durham University, LLB, Law with Economics
  • BPP Law School, LPC
Admissions
  • The Senior Courts of England & Wales in 2006
  • Eastern Caribbean Supreme Court (British Virgin Islands) in 2014